Analyst & Firm	Company	Rating & Price Target	Upside / Downside
Thomas ChongJefferies	BIDU Baidu	BUY$128	41.97% Upside
Yigal NochomovitzCiti	LENZ LENZ Therapeutics	BUY$44	75.65% Upside
David RomanGoldman Sachs	TDOC Teladoc	BUY$16	22.23% Upside
Michael LasserUBS	SPGI S&P Global	BUY$640	18.35% Upside

Daily Sell Ratings

Analyst & Firm	Company	Rating & Price Target	Upside / Downside
Joe RitchieGoldman Sachs	CGNX Cognex	SELL$35	6.25% Upside
Kate McShaneGoldman Sachs	FL Foot Locker	SELL$21	8.86% Upside
Benjamin SwinburneMorgan Stanley	ROKU Roku	SELL$75	-21.05% Downside
Jamie RolloMorgan Stanley	CCL Carnival	SELL$25	-2.10% Downside

Full List of Stock Ratings

(Feb 18, 2025)

Analyst Performance

Any

Analyst Rating

Any

Upside / Downside

Any

Action

Any

Market Cap

Any

Analyst & Firm	Company	Rating & Price Target	Upside / Downside	Average Return	Action	Date	Article
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $128	―	7.90%	Reiterated	2025-02-19
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $7→$6	―	15.10%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $18	―	7.70%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $240→$257	―	1.00%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $155→$150	―	10.80%	Reiterated	2025-02-18
David AmsellemPiper Sandler	BIIB Biogen	HOLD $138→$135	―	-0.10%	Reiterated	2025-02-18	Biogen price target lowered to $135 from $138 at Piper Sandler
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $80→$87	―	8.40%	Reiterated	2025-02-18
Matthew Farrell CFAPiper Sandler	DKNG DraftKings	BUY $48→$60	―	-1.60%	Reiterated	2025-02-18	DraftKings price target raised to $60 from $48 at Piper Sandler
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $42	―	4.60%	Downgraded	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $20→$28	―	18.30%	Reiterated	2025-02-18
Louie DiPalmaWilliam Blair	PSN Parsons	BUY	―	-20.90%	Upgraded	2025-02-18	Parsons upgraded to Outperform from Market Perform at William Blair
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	SELL $19	―	17.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $221→$242	―	0.80%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $22	―	12.00%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $440	―	3.50%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $307	―	13.10%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $285	―	3.50%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $130→$132	―	13.10%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	SELL $110→$90	―	1.00%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $75	―	32.90%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $238	―	7.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $49	―	12.50%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $60→$63	―	0.10%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $115	―	3.50%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $11.5	―	17.00%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $430	―	3.80%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $455	―	13.10%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $102	―	13.10%	Reiterated	2025-02-18
Christopher RaymondPiper Sandler	ACRS Aclaris Therapeutics	BUY $13	―	0.00%	Reiterated	2025-02-18	Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $35	―	13.30%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $2→$2.2	―	11.90%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $675→$750	―	15.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $285→$277	―	11.10%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $153→$160	―	15.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $95→$100	―	15.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $95→$100	―	15.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $86→$90	―	15.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $79→$82	―	6.20%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $60→$64	―	11.90%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $54→$60	―	3.50%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $18	―	14.00%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $63	―	18.60%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $75	―	4.60%	Reiterated	2025-02-18
Yi ChenH.C. Wainwright	OKYO OKYO Pharma Limited Sponsored ADR	BUY $7	―	-13.50%	Reiterated	2025-02-18	H.C. Wainwright Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $11.5	―	6.70%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $244	―	2.80%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $510→$540	―	10.90%	Reiterated	2025-02-18
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $150→$170	―	25.70%	Reiterated	2025-02-18
Joseph SpakUBS	AXL American Axle	HOLD $6.5→$6	―	-7.90%	Reiterated	2025-02-18	American Axle price target lowered to $6 from $6.50 at UBS
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $60→$38	―	4.20%	Reiterated	2025-02-18

Rows:

Ready for the Full Picture?Your current plan limits your access to top-tier analyst ratings. Subscribe to Premium now and unlock the full range of ratings from the highest-ranked analysts on Wall Street. Don't let partial views limit your market research potential - upgrade today!

Upgrade Now Plans & Pricing